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West Nile virus is a mosquito-borne, neurotropic flavivirus that causes encephalitis in humans and animals. Since being introduced into
the Western hemisphere in 1999, WNV has spread rapidly across North America, identifying this virus as an important emerging pathogen. In
this study, we developed a DNA-launched infectious molecular clone of WNV that encodes a GFP reporter gene. Transfection of cells with
the plasmid encoding this recombinant virus (pWNII-GFP) resulted in the production of infectious WNV capable of expressing GFP at high
levels shortly after infection of a variety of cell types, including primary neurons and dendritic cells. Infection of cells with WNII-GFP virus
was productive, and could be inhibited with both monoclonal antibodies and interferon-h, highlighting the potential of this system in the
development and characterization of novel inhibitors and therapeutics for WNV infection. As expected, insertion of the reporter gene into the
viral genome was associated with a reduced rate of viral replication, providing the selective pressure for the development of variants that no
longer encoded the full-length reporter gene cassette. We anticipate this DNA-based, infectious WNV reporter virus will allow novel
approaches for the study of WNV infection and its inhibition both in vitro and in vivo.
D 2005 Elsevier Inc. All rights reserved.
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West Nile virus (WNV) is a neurotropic flavivirus within
the Japanese encephalitis antigenic complex that is respon-
sible for causing West Nile encephalitis in humans
(reviewed in reference (Brinton, 2002)). Entry of WNV
into cells is thought to occur via interaction of the viral
envelope protein (E) with an unidentified cellular receptor
(Chu and Ng, 2003). Once bound, virus is internalized and
trafficked into an endosomal compartment where fusion
occurs in a pH-dependent process (Gollins and Porterfield,
1986; Kimura et al., 1986). In the cytoplasm of infected
cells, the 11 kb positive-stranded viral genomic RNA is
translated into a single polyprotein that is subsequently0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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(capsid, pre-membrane (prM), and E) and seven non-
structural (NS) proteins (reviewed in reference (Rice,
1996)). As with other flaviviruses, the sequence encoding
the WNV polyprotein is flanked by two untranslated regions
(UTRs) that are required for efficient translation and
genomic RNA replication (Cahour et al., 1995; Khromykh
et al., 2003; Lai et al., 1991; Men et al., 1996). Viral RNA
and protein synthesis occurs in association with intracellular
membranes (Mackenzie and Westaway, 2001; Mackenzie et
al., 1999), leading to the assembly and release of enveloped
virions with icosahedral symmetry that are approximately
50 nm in diameter (Mukhopadhyay et al., 2003).
WNV is maintained in an enzootic cycle between birds
and mosquitoes, although many other vertebrate species can
be infected including humans and horses (Marfin and
Gubler, 2001). While the majority of individuals exposed
to WNV remain asymptomatic, a spectrum of disease has
been reported that ranges from a mild febrile illness to005) 28–40
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factors that influence the severity of WNV infection include
age and the immune status of the affected individual
(Chowers et al., 2001; Nash et al., 2001; Tsai et al.,
1998). Currently, no specific therapy for WNV infection has
been developed and treatment is supportive in nature.
While endemic in parts of Africa, Europe, Asia and the
Middle East, introduction of WNV into the Western Hemi-
sphere did not occur until the late summer of 1999, when 59
clinical cases were reported in the New York City area
(Lanciotti et al., 1999; Marfin and Gubler, 2001). WNV has
since spread rapidly across North America, infecting more
than 9000 individuals in 2003 alone. To date, the 2004
epidemic of WNV in the US has involved approximately
2470 laboratory-confirmed human cases of WNV, resulting
in at least 88 fatalities. The spread of WNV across much of
the United States, Canada and Mexico in mosquito, avian
and mammalian species makes this virus an important
emerging pathogen in the Western Hemisphere.
At present, relatively little is known about WNV tropism
and pathogenesis. While WNV is clearly neurotropic in vivo,
it also infects several visceral organs including lymph node,
spleen and kidney (Diamond et al., 2003a). WNV also
exhibits a broad cellular tropism in vitro (Brinton, 2002). The
cellular targets for WNV in non-neural tissues in vivo have
not yet been determined, nor have the mechanisms by which
WNV gains access to the central nervous system from these
peripheral sites of viral replication. While the use of congenic
strains of mice have proven to be a powerful tool for
identifying host factors that contribute to WNV pathogenesis
(Diamond et al., 2003a, 2003b; Shrestha et al., 2003; Wang et
al., 2003), little progress has been made on the development
of rapid and quantitative methods to study the viral
determinants of WNV tropism and pathogenesis in vivo.
In this study, we have developed an infectious, replication
competent WNV genome that encodes a reporter gene. The
gene encoding green fluorescent protein (GFP) was clonedFig. 1. Schematic of the WNII-GFP reporter virus. A plasmid encoding an infectio
capable of expressing GFP using standard transfection methods. A previously desc
as a starting point for the construction of two plasmids encoding WNV: WNII-Not
activity of the CMV promoter, allowing the production of virus particles following
the terminus of the viral genomic RNA are determined by the transcriptional start si
constructed that encodes a unique NotI restriction endonuclease recognition sit
composed of GFP under the translational control of the EMCV IRES was clonedinto the 3VUTR of the viral genome under the translational
control the of internal ribosome entry site (IRES) of
encephalomyocarditis virus (EMCV). Transfection of cells
with this infectious DNA plasmid resulted in the production
of infectious WNV capable of mediating high-level expres-
sion of GFP in several different cell types, including primary
rat neurons and human monocyte derived dendritic cells.
This GFP-expressing WNV is a novel tool that provides a
quantitative approach for investigating many aspects and
inhibitors of the WNV lifecycle.Results
Development of an infectious WNV that encodes GFP
To construct a DNA plasmid encoding an infectious
WNV reporter virus, we modified a molecular clone of a
lineage II strain of WNV (Yamshchikov et al., 2001a,
2001b). This vector, called SP6WN/Xba, encodes an
infectious WNV cDNA under the control of the bacter-
iophage SP6 promoter (Fig. 1) (Yamshchikov et al., 2001a,
2001b). Using this vector system, the production of virus
particles is accomplished after in vitro transcription of full-
length, capped, viral RNA and subsequent transfection.
However, recent studies indicate that the cDNA of a
flavivirus can be engineered downstream of a constitutive
eukaryotic promoter provided that the transcribed RNA
begins and ends with the highly conserved terminal
nucleotides of the viral genome (Hall et al., 2003; Liu et
al., 2003; Mishin et al., 2001; Yamshchikov et al., 2001a,
2001b). Virus production using vectors with this config-
uration involves standard DNA transfection methods and
eliminates the requirement for production and purification
of genomic-length, 11 kb RNA molecules in vitro. To
construct an infectious WNV plasmid, we modified
SP6WN/Xba so that the WNV genome was placed underus WNV genome was modified to allow the production of infectious WNV
ribed molecular clone of the lineage II WNV strain (956 D117 3B) was used
and WNII-GFP. In both plasmids, the expression of WNV is regulated by the
transfection of DNA into cells. In this configuration, the ribonucleotides at
te of CMVand by cleavage of the ribozyme of HDV. A variant of WNV was
e. To generate a WNV capable of expressing a reporter gene, a cassette
into this unique NotI site to produce WNII-GFP.
Fig. 2. Infectious titer of the WNII-GFP reporter virus. (A) Production of
infectious WNV in transfected HEK-293T cells. The infectious titer of
WNII-Not and WNII-GFP virus particles produced following transfection
of HEK-293T cells with plasmids encoding the full-length viral genome
was determined by plaque assay. Virus containing supernatants were
harvested from the producer cells at the indicated time and added to BHK-
21 cell monolayers. One hour later, the supernatant was removed and
replaced with 2% low melting point agarose in a-MEM media with FBS.
Plaques were fixed and enumerated after 3 days of infection. These results
are representative of two separate assays using two different stocks of
plasmid DNA. (B) Growth of WNII-Not and WNII-GFP viruses in BHK-21
cells. The kinetics of virus production following infection of target cells
was determined by infecting BHK-21 cells with WNII-Not or WNII-GFP
viruses at a multiplicity of 0.05. Virus was added to cells and allowed to
attach for 4 h, followed by three washes with DMEM. At the indicated
times, virus was harvested and frozen until assayed. The titer of virus
released into the supernatant was determined by plaque assay on BHK-21
cells performed in duplicate (plaques were enumerated 3.5 days post-
infection). The data presented represent the mean titer of two different
growth curve experiments, with error bars representing the standard error.
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taken to engineer the terminal nucleotides of the viral
genome precisely at the transcriptional start site of the CMV
promoter. The generation of a precise 3Vend of the genome
was accomplished by ribozyme-mediated post-transcrip-
tional cleavage of the RNA (Fodor et al., 1999; Khromykh
et al., 2003; You et al., 2001; Zhang et al., 2001). In
addition, a unique NotI restriction site was inserted into the
3V UTR, generating the DNA-launched infectious clone
pWNII-Not (Fig. 1). This site was then used for the insertion
of an IRES-driven reporter gene cassette to create a WNV
genome capable of expressing GFP in infected cells
(pWNII-GFP).
Production of infectious WNV capable of expressing GFP in
infected cells
To evaluate the ability of our DNA plasmids to produce
infectious WNV, HEK-293T cells were transfected with
plasmids pWNII-Not or pWNII-GFP and the amount of
infectious virus released into the supernatant was measured
over the course of 3 days by plaque assay (Fig. 2A). The
production of WNV from pWNII-Not-transfected cells was
rapid. Within 24 h of transfection, viral titers in the
supernatant were determined to be greater than 106
plaque-forming units (pfu) per ml and continued to increase
modestly thereafter. The level of virus production achieved
with this plasmid-based system is similar to published
values for the amount of virus produced following the
infection of Vero cells with the same strain of WNV
(Yamshchikov et al., 2001a, 2001b). This suggests that
neither the use of a DNA plasmid and eukaryotic promoter
to produce the viral RNA, nor the addition of the NotI
restriction site in the 3V UTR, resulted in significant
attenuation of virus replication or production. In contrast,
during the first 24 h post-transfection, the kinetics of WNII-
GFP production was markedly slower (350-fold) than that
observed with WNII-Not. However, by 72 h post-trans-
fection, WNII-GFP titers reached 106 pfu per ml, demon-
strating an ability to produce this virus at relatively high
titer. To complement these studies, growth curves of WNII-
Not and WNII-GFP viruses were performed in both
mammalian (Fig. 2B) and insect cell lines (data not shown).
In both cases, the overall titers achieved following WNII-
GFP infection were approximately 10- to 20-fold reduced as
to infections compared with the control WNII-Not virus.
Together, the delayed kinetics of virus production, com-
bined with the lower overall titer of the virus, suggests that
the insertion of the 1.3 kb IRES-GFP cassette into the 3V
UTR impacts the rate of virus production.
To evaluate the ability of pWNII-GFP to produce virus
particles capable of expressing GFP, the level of reporter
gene expression in both transfected producer cells and
infected target cells was evaluated by flow cytometry. HEK-
293T cells were transfected with pWNII-Not or pWNII-GFP
and 48 h later, both the cells and virus containing super-natants were harvested. Transfected HEK-293T cells were
analyzed by flow cytometry for GFP expression. The
majority of cells transfected with pWNII-GFP expressed
high levels of GFP (%GFP positive: 95.46%; geometric
mean channel fluorescence (GMCF): 320.25) (Fig. 3A). As
anticipated, neither untransfected controls, nor cells trans-
fected with pWNII-Not, expressed GFP (%GFP positive:
0.08% and 0.41%, respectively). To determine whether the
virus particles released from pWNII-GFP transfected cells
were capable of promoting GFP expression in target cells,
BHK-21 cells were infected with the HEK-293T WNII-GFP
Fig. 3. Expression of GFP from a replication competent WNV viral genome. (A) DNA plasmids encoding WNII-Not and WNII-GFP were transfected into
HEK-293T cells. At 48 h post-transfection, supernatants were harvested and used to infect BHK-21 cells. The producer cells were then harvested and analyzed
for GFP expression using flow cytometry. A histogram plotting green fluorescence of WNII-Not (shaded) and WNII-GFP (dark line) transfected cells is shown.
(B) The expression of GFP in infected BHK-21 target cells was measured by flow cytometry 48 h post-infection. (C) Expression of GFP in infected BHK-21
target cells was also studied by immunofluorescence analysis. BHK-21 cells were infected at a multiplicity of one (1 pfu per cell) with WNII-GFP containing
supernatant. At 30 h post-infection, cells were washed, fixed in 2% paraformaldehyde, and permeabilized with 0.1% Triton. Cells were stained with a
monoclonal antibody reactive with the WNV E protein (4G2) (Falconar, 1999), and expression of GFP was examined.
Fig. 4. Kinetics of WNII-GFP reporter gene expression. The kinetics of
GFP expression following WNII-GFP infection was monitored following
the infection of BHK-21 cells. 2.5  104 BHK-21 cells were plated in a 48-
well plate 18–24 h prior to infection. Cells were infected with 105 pfu of
WNII-GFP in a total volume of 200 Al of GMEM for one hour. Unbound
virus was removed with three 400 Al washes with PBS. Cells were then
cultured for the indicated periods in 200 Al of GMEM. At the indicated
times, cells were harvested and fixed in 2% paraformaldehyde diluted into
PBS. The average percentage of cells infected in duplicate wells is plotted.
These results are representative of five independent experiments performed
with two different stocks of WNII-GFP.
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infection (Fig. 3B). GFP expression was readily detected in
BHK-21 cells infected with WNII-GFP (percent GFP
positive: 95.55%; GMCF: 623.74), but not those infected
with supernatants from mock or pWNII-Not transfected
producer cells (%GFP positive: 0.05% and 0.73%, respec-
tively). Similar results were obtained using indirect immu-
nofluorescence microscopy of infected HeLa cells (Fig. 3C).
Infection of BHK-21 cells with either WNII-Not or WNII-
GFP resulted in the expression of WNV E protein in
virtually all of the cells, but GFP expression was observed
in only WNII-GFP infected target cells. That the majority of
WNII-GFP infected cells expressed detectable levels of both
WNV E protein and GFP demonstrated that a significant
fraction of the WNII-GFP virus produced by HEK-293T
cells was capable of expressing GFP in infected cells.
Kinetics of GFP expression in WNII-GFP infected cells
The infection of cells with WNII-GFP resulted in robust
levels of GFP expression. To determine the kinetics of GFP
expression in infected cells, BHK-21 cells were infected
with WNII-GFP at an MOI of four. At the indicated times,
cells were washed, harvested, and analyzed by flow
cytometry. The expression of GFP in infected target cells
was observed as early as 14 h post-infection (data not
shown) and increased over time. By 40 h post-infection,
virtually all cells in the culture expressed high levels of GFP
(Fig. 4). The replication cycle of WNV is relatively short
with progeny virus particles released into the media within
the first 14 h of infection (Fig. 2B) (Shrestha et al., 2003).
Thus, during the time required to achieve maximal GFP
expression in infected cells, multiple rounds of WNV
replication may occur.Stability of WNII-GFP in vitro
The positive stranded RNA genome of WNV is 11,000
nucleotides in length. Modification of this genome to
encode a reporter gene increased the overall size of the
viral RNA by 1.3 kb and reduced the rate of viral replication
(Fig. 2). Therefore, it would not be surprising if variants
would arise during the course of prolonged virus propaga-
tion in culture in which all or a portion of the reporter gene
was lost, thus reducing overall genome size, which in turn
may result in more rapid viral replication. To investigate the
Fig. 5. Stability of WNII-GFP in vitro. The stability of GFP expression
from WNII-GFP was evaluated in vitro using two methods. Virus
containing supernatants were harvested from WNII-GFP transfected into
HEK-293T cells at 24 h post-transfection and titered by plaque assay. Serial
passage of WNII-GFP was performed by infecting HEK-293T cells with
WNII-GFP at a multiplicity of 0.1. Two days later, the viral containing
supernatants were harvested and the infected cells analyzed by flow
cytometry. The percentage of cells infected with WNII-GFP was
determined by monitoring both GFP expression and WNV E protein
expression. WNV E protein expression was monitored using intracellular
staining with mAb WNV E1.E6. Three additional passages were performed.
The results are representative of three independent experiments.
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multiple rounds of virus replication, serial passage of WNII-
GFP was performed. WNII-GFP was produced by trans-
fection of HEK-293T cells, titered with a plaque assay, and
used to infect HEK-293T cells at a multiplicity of 0.1.
Infected cells were then cultured to allow for virus
production and spread. At 48 h post-infection, virus
containing supernatants and infected cells were harvestedFig. 6. Presence of recombinant forms of WNII-GFP in infected cells. BHK-21 cel
for 1 h and washed four times in PBS. At the indicated times, cells were harvested
that flanked the location of the IRES-GFP reporter gene cassette (shown as triangle
(B) Truncated PCR products were isolated from the gel, cloned using a topoisome
structure of the PCR fragments with truncations shown to scale as spaces betweefor analysis. The passaged virus was titered and used to re-
infect HEK-293T cells to allow for additional rounds of
virus replication. A total of four such passages were
performed, accounting for approximately 8 rounds of
replication based on a 24-hour replication cycle (Fig. 2B).
At each passage, the infected cells were analyzed by flow
cytometry to determine the percentage of cells expressing
GFP and WNV E protein (Fig. 5). We found that while the
percentage of infected cells expressing E protein remained
constant, the fraction expressing both E protein and GFP
declined with each passage, with approximately 10% of the
cells expressing both proteins after 96 h in culture.
The loss of GFP expression observed in infected cultures
over time may reflect inactivating point mutations or
deletions of portions of the reporter gene cassette. To detect
the presence of truncated forms of the WNII-GFP genome,
we tracked the fate of the reporter gene cassette during
infection. BHK-21 cells were infected with WNII-Not or
WNII-GFP virus at a multiplicity of 0.1. At the indicated
times after infection, total cellular RNA was isolated from
infected cells and used as a template in a RT-PCR reaction
with primers that spanned the IRES-GFP cassette. While
amplification of RNA from WNII-GFP infected cells
isolated at early time points of infection resulted in the
production of the expected 1.3 kb DNA band, at later time
points, the production of smaller fragments was also
observed, albeit at very low frequency (Fig. 6A). Several
of these smaller amplification products were cloned and
sequenced and revealed the presence of a heterogeneousls were infected at a multiplicity of 0.1 with either WNII-Not or WNII-GFP
and total RNAwas isolated. (A) RT-PCR was performed with a primer set
s). The resulting PCR products were resolved by agarose gel electrophoresis.
rase mediated cloning vector, and sequenced. Shown to scale in black is the
n the two ends of the PCR fragment.
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Thus, selection for genomes encoding these small deletions
in the reporter gene cassette may be responsible for the
decline in GFP expression that occurs as virus is propagated
in culture. Together, these results indicate that while the
WNV genome can tolerate the introduction of a reporter
gene cassette in this position, it reduces the rate of viral
replication (Fig. 2) eventually resulting in the selection of
variants that no longer encode a functional reporter gene
cassette (Figs. 5 and 6).
Infection of primary cells with WNII-GFP
Flaviviruses have a broad tropism in vitro (Brinton,
2002). During the course of these studies, a survey of a
modest number of cell lines (e.g., Vero, 293T, HeLa, QT-6,
CCC, U87, BHK-21, K562, Raji) revealed that they were all
permissive for infection by WNII-GFP, although with
varying efficiency (data not shown). An interesting appli-
cation of WNII reporter viruses is their potential for the
analysis of WNV tropism in vivo as well as in primary cell
types studied ex vivo. To confirm that WNII-GFP can infect
and express GFP in physiologically relevant cell types, we
infected human dendritic cells and rat sympathetic motor
neurons from the superior cervical ganglion.
Dendritic cells (DCs) are professional antigen presenting
cells required for the induction of primary immuneFig. 7. Infection of primary cell types ex vivo that model targets of in vivo infe
dendritic cells were produced by treatment of elutriated monocytes with GM-CS
to infection. Both mature and immature DCs were infected with WNII-GFP at a
0.74 mg/ml stock), and analyzed by flow cytometry at day three. (B) WNII-G
neurons were harvested from rat pups and then mock infected or infected in vit
fixed and visualized directly for GFP fluorescence (A and C) or processed for
antibody (B and D).responses. Immature dendritic cells (iDCs) are cells of the
myeloid-lineage that are thought to develop from monocytes
that emigrate from the blood and patrol the periphery and
are specialized for antigen uptake. In humans, two major
types of iDCs have been defined based on their pattern of
antigen expression and the area of the body that they patrol:
the interstitial DCs found in the skin dermis and elsewhere,
and the Langerhans cells of the skin epidermis (reviewed in
(Liu, 2001)). Monocyte-derived dendritic cells (MDDCs), a
model of the interstitial type of iDCs found in vivo, were
produced in vitro by the treatment of elutriated human
monocytes with IL-4 and GM-CSF. MDDCs were assayed
for the expression of several cell surface antigens associated
with iDCs such as DC-SIGN (Geijtenbeek et al., 2000) and
CD11c (Pickl et al., 1996). Immature DCs were plated and
infected with WNII-GFP at a multiplicity of one. In three
separate experiments, employing cells from two different
donors, we found that a modest number of iDCs expressed
GFP following infection (Fig. 7A). This infection could be
blocked by pre-incubation of the virus with a previously
characterized, neutralizing mAb, 7H2 (Beasley and Barrett,
2002). As expected, GFP-expressing cells were not
observed in uninfected controls. The ability to infect mature
dendritic cells (mDCs) was also evaluated. In response to
bdanger signalsQ such as lipopolysaccharide (LPS) and other
pathogen-derived molecules, iDCs migrate to the lymph
nodes and upregulate their surface expression of CD83,ction. (A) Infection of human MDDCs with WNII-GFP. Immature human
F and IL-4. Mature DCs were produced by treatment with LPS 24 h prior
MOI of 1 in the presence or absence of the MAb 7H2 (1/200 dilution of a
FP infection of rat superior cervical ganglia (SCG) motor neurons. SCG
ro with WNII-GFP at an MOI of 50. At 6 days post-infection, cells were
immunofluorescence using a polyclonal rat anti-WNV polyclonal primary
Fig. 8. Inhibition of WNII-GFP infection. (A) Neutralization of WNII-GFP
infection by monoclonal antibodies. The potency of two previously
described neutralizing monoclonal antibodies that recognize the domain
III portion of WNV E protein was evaluated (Beasley and Barrett, 2002).
Serial 10-fold dilutions of mAb antibody were incubated for 1 h at room
temperature with 1000 pfu of WNII-GFP (200 Al total volume) and then
used to infect approximately 5  104 pre-plated BHK-21 cells. Each
neutralization condition was performed in triplicate. At 36 h post-infection,
target cells were harvested and fixed in 2% paraformaldehyde. Analysis of
the percentage of infected cells expressing GFP under each condition was
determined by flow cytometry. The percent infection ( y axis) was
computed by solving the equation ((% infected cells in the presence of
antibody) / (% infected cells in the absence of antibody)  100). Error bars
represent the standard error, while dashed lines express the 95% confidence
interval of a non-linear regression analysis performed using Graph Pad
Prism. (B) Inhibition of WNII-GFP infection by type I interferon. HEK-
293T and HeLa cells were treated with the indicated concentrations of
IFN-h for 24 h prior to exposure to virus. Cells were then infected in
quadruplicate with WNII-GFP at a multiplicity of one. At 36 h, infected
cells were harvested and analyzed by flow cytometry. Percent infection was
calculated and non-linear regression performed as described above: the
standard error and the 95% confidence interval for the regression analysis is
displayed (error bars and dotted line, respectively). These results are
representative of two independent experiments.
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CD86 (Mellman and Steinman, 2001). These activated
mDCs strongly stimulate antigen-specific T-cell activation
and proliferation. Interestingly, activation of iDCs with LPS
rendered the resulting mDCs non-permissive for WNII-GFP
infection. The expression of IFN-h following LPS treatment
may account for the non-susceptibility of stimulated
dendritic cells to WNV infection as discussed below
(Oshiumi et al., 2003).
WNV is a neurotropic virus that infects a broad range of
neuronal cells including motor neurons (Shrestha et al.,
2003). To confirm that WNII-GFP could infect neuronal
cells, rat superior cervical ganglion sympathetic motor
neurons (SCG) were incubated with WNII-GFP and assayed
for GFP and viral antigen expression. These cells can be
persistently infected by the New York 2000 lineage I strain
of WNV, resulting in the long-term release of infectious
virus in the absence of cell death (M. Samuel and M.
Diamond, unpublished results). Similar results were
obtained with WNII-GFP-infected SCG neurons. We found
that 6 days after infection with WNII-GFP, almost all SCG
neurons in the culture strongly expressed both GFP and
WNV E proteins (Fig. 7B). Thus, WNII-GFP was able to
directly infect neurons, a physiologically relevant target for
WNV infection.
Antibody and interferon-mediated inhibition of WNV entry
and replication
The robust and rapid expression of GFP following
infection of cells with WNII-GFP, coupled with the
quantitative power of flow cytometry, makes this reporter
virus a powerful tool to study the inhibition of WNV entry
and replication. As a proof of principle, we evaluated the
utility of WNII-GFP as a rapid method for the detection of
antibodies capable of blocking infection. To do this, we
investigated the ability of two previously characterized
MAbs (7H2 and 5H10) to block WNV infection. Both 7H2
and 5H10 are thought to neutralize WNV infection through
interactions with the domain III region of the E protein
(Beasley and Barrett, 2002). To measure antibody-mediated
neutralization, approximately 1000 pfu of WNII-GFP was
incubated in the presence of 10-fold serial dilutions of
antibody for an hour prior to infection of pre-plated BHK-21
cells. After 36 h, the infected cells were analyzed by flow
cytometry. Incubation of WNII-GFP with antibody prior to
infection resulted in a dose-dependent reduction in the
number of infected target cells, with a 50% reduction of
infection being observed at a concentration of 1.03 ng/ml
(95% confidence: 0.92–1.16 ng/ml) and 3.05 ng/ml (95%
confidence: 2.26–4.12 ng/ml) (Fig. 8A). Thus, infection of
cells with flaviviruses that contain reporter genes can be
used as an alternative, quantitative test to measure antibody-
mediated virus neutralization.
The antiviral activity of type I interferons (IFNa and h)
have been demonstrated for several different flaviviruses invitro (Anderson and Rahal, 2002; Diamond and Harris,
2001; Diamond et al., 2000b) and in vivo (Brooks and
Phillpotts, 1999; Cole and Wisseman, 1969; Johnson and
Roehrig, 1999). The mechanism of inhibition by interferon
is not completely understood but appears to involve
blocking viral RNA translation and replication after
introduction of the viral genome into the cytoplasm of
the infected cell (Anderson and Rahal, 2002; Diamond and
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utility of WNII-GFP for the analysis of inhibitors at a post-
entry step in the flavivirus lifecycle, we tested the ability of
IFN-h to block WNII-GFP infection. HeLa and HEK-293T
cells were treated with a range of concentrations of IFN-h
for 12 h and then infected with WNII-GFP (Fig. 8B).
Although treatment of both cell types with high concen-
trations of IFN-h inhibited infection of WNII-GFP, HeLa
cells were significantly more sensitive to IFN-h mediated
inhibition at lower concentrations due to the fact that HEK-
293T cells responded poorly to IFN-h.Discussion
In this study, we describe the construction of an
infectious molecular clone of WNV capable of expressing
high levels of GFP in infected cells. The design of WNII-
GFP took advantage of several advances in construction of
RNA virus infectious clone technology. In the majority of
flavivirus molecular clones described to date, the viral
genome is cloned downstream of a bacteriophage promoter
(Hurrelbrink et al., 1999; Kapoor et al., 1995; Kinney et
al., 1997; Mandl et al., 1998; Polo et al., 1997; Pur et al.,
2000; Rice et al., 1989; Shi et al., 2002a, 2002b;
Sumiyoshi et al., 1992). To produce virus particles using
these systems, genomic length, 11 kb RNA is transcribed
and purified in vitro, followed by transfection into cells.
Alternatively, an binfectiousQ DNA approach has been
developed for Kunjin and Japanese encephalitis viruses in
which the viral genome is cloned under the control of a
eukaryotic promoter, allowing the production of infectious
virus particles using conventional plasmid transfection
methodologies (Hall et al., 2003; Liu et al., 2003; Mishin
et al., 2001; Yamshchikov et al., 2001a, 2001b). A key
feature of this approach is that the RNAs produced in
transfected cells are full-length and retain the authentic,
highly conserved terminal nucleotides of the viral genome
that are required for replication (Khromykh et al., 2001,
2003; You et al., 2001; Zhang et al., 2001). A significant
advantage of this DNA-launched approach for the design
of RNA virus vectors is the straightforward method for
virus production. However, the reported instability of
plasmids encoding full-length flavivirus genomes, exacer-
bated by a low level of eukaryotic promoter activity in
bacteria, may limit the widespread application of this
approach (Mishin et al., 2001). To evaluate both strategies,
we constructed WN reporter viruses under the control of
either the SP6 (data not shown) or CMV promoter. While
preliminary studies with SP6-containing vectors demon-
strated that infectious WNV encoding a reporter gene could
be produced, this method was not efficient in our hands.
While not characterized exhaustively, we suspect a failure
to produce high titer WNV stocks using this approach was
due to inefficient synthesis and transfection of 11 kb,
infectious RNA. As a result, we focused on developing aDNA-launched approach that allows the production of
virus particles following the high-efficiency transfection of
cells with plasmid DNA using well-established methods,
resulting in the production and characterization of the first
DNA-launched molecular clone of WNV described to date.
The straightforward transfection methods used to produce
virus with this vector system allows the rapid introduction
and characterization of mutations into the viral genome,
which will greatly facilitate studies of the structure
and function of WNV proteins during virus entry and
replication.
The ability to rapidly and quantitatively monitor WNV
entry and replication by virtue of reporter gene activity
suggests numerous applications of reporter viruses for the
analysis of several facets of flavivirus biology in vitro,
including the development of novel therapeutics. Several
different classes of entry inhibitors that block HIV-1
infection have been developed and shown to be efficacious
in vitro and when evaluated in human clinical trials
((Lalezari et al., 2003; Lazzarin et al., 2003), reviewed
in reference (Pierson and Doms, 2003)). The demonstrated
clinical success of entry inhibitors, coupled with recent
structural insights into the mechanisms of how the class II
fusion proteins of alpha- and flaviviruses mediate mem-
brane fusion (Bressanelli et al., 2004; Gibbons et al., 2004;
Modis et al., 2003, 2004), suggests that the development
of compounds that block virus entry will be an active area
of research.
In addition to small molecule inhibitors, the development
of immunotherapeutic approaches to WNV infection also
holds promise for treatment of affected individuals. The
development of a humoral response is an important aspect
of protection from and clearance of flavivirus infection
(reviewed in (Diamond et al., 2003b)). The standard method
for detecting neutralizing antibodies to flaviviruses is the
plaque reduction neutralization test (PRNT). Using this
approach, the ability of an antibody to bind virus and
neutralize its infectivity is measured as a reduction in the
number of plaques formed following infection. In compa-
rison to the PRNT, the application of reporter viruses for the
study of antibody-mediated neutralization has several
advantages including speed (36 h vs. 72 h), an ability to
study neutralization on cell types incompatible with the
formation of plaques, and the increased quantitative power
associated with the ability to count large numbers of
infection events using flow cytometry. The precision with
which antibody-mediated neutralization can be measured
using WNII-GFP will allow new approaches and insights
into the mechanisms of neutralization and enhancement of
infection.
While replication-competent flaviviruses encoding
reporter genes have not yet been described, sub-genomic
replicons encoding reporter genes have been developed
for several viral systems, including WNV (Blight et al.,
2000; Khromykh and Westaway, 1997; Lohmann et al.,
1999; Pang et al., 2001; Shi et al., 2002a, 2002b;
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Despite the deletion of a large portion of the genome
encoding the viral structural proteins, replicon RNAs
retain the ability to replicate in the cytoplasm of trans-
fected cells, providing a platform upon which viral
replication can be investigated (reviewed in (Westaway
et al., 2003)). In addition, an elegant body of work by
Khromykh et al. (1998) demonstrates that replicons can
be packaged into virus-like particles by complementation
with structural genes provided in trans by alphavirus
vectors (Harvey et al., 2004). While incapable of
productive infection, virus-like particles encapsidating
replicon RNA offer considerable potential for the study
of flavivirus entry, replication and novel inhibitors. The
development of WNII-GFP complements these approaches
by allowing the study of WNV during a productive
infection using an infectious virus capable of initiating
multiple rounds of replication.
A powerful application of WNII-GFP is the study of
WNV tropism in vivo. The initial cellular targets of WNV
infection and viral amplification in the periphery have not
been determined, nor has the mechanism by which the
virus penetrates the CNS (reviewed in (Diamond et al.,
2003b)). Infection of mice with WNII-GFP will provide a
straightforward and quantitative approach for the identify-
ing infected cells in vivo. Identification of the initial
cellular targets of WNV infection, how these cells migrate
in the days following exposure to WNV, or cells that are
productively infected in visceral organs, would constitute
a significant advance. In addition, the contribution of
direct and bystander killing of neurons or other WNV
targets could be determined by virtue of the fact that GFP
expression occurs only in cells actively replicating WNII-
GFP. The applications of WNII-GFP in vivo are limited
in part by the instability of the viral genome encoding a
large reporter gene cassette. Our analysis of WNII-GFP
stability in vitro suggest the genome will be stable
enough to allow the identification of the initial targets
of WNV infection during the first 3–4 days of infection.
Characterizing the behavior of WNII-GFP in vivo is
underway.Materials and methods
Construction of a DNA plasmid encoding an infectious
WNV cDNA that expresses GFP
A full-length molecular clone of a lineage II strain of
WNV was modified in two ways to allow the production of
virus encoding a reporter gene following the transfection of
cells with plasmid DNA (Wengler and Gross, 1978;
Yamshchikov et al., 2001a, 2001b). First, to allow the
production of WNV using routine transfection procedures,
the SP6 bacteriophage promoter that controls expression of
the WNV genome in the parental SP6WN/Xba plasmid wasreplaced with the highly active immediate-early promoter
of CMV. Second, a reporter gene was inserted into the 3V
UTR under the translational control of the EMCV IRES.
Our initial efforts focused on the development of viruses
encoding GFP due to the relatively small size of this
reporter gene, and the ease with which it can be visually
detected and quantified using flow cytometry. Construction
of a GFP-expressing molecular clone, pWNII-GFP, was
accomplished in several stages using standard molecular
techniques. The rationale for the cloning strategy used to
construct pWNII-GFP reflects the fact that two different
WNV reporter systems, an infectious molecular clone
encoding GFP and a series of sub-genomic replicons (T.
Pierson and R. Doms, manuscript in preparation), were
constructed in parallel and designed to share many common
cloning intermediates. Therefore, while the methods
reported here describe the steps actually taken to construct
pWNII-GFP, they do not necessarily represent the most
direct method for constructing pWNII-GFP from the
SP6WN/Xba parental vector.
Insertion of a novel restriction site into the 3VUTR of WNV
The first step in construction of pWNII-GFP was the
introduction of a unique NotI restriction site into the 3VUTR
of the viral genome that allowed the subsequent introduction
of a reporter gene. This site was introduced 24 nucleotides
downstream of the stop codon of the WNV polyprotein
based on strategies employed in several flavivirus replicon
systems (Khromykh and Westaway, 1997; Shi et al., 2002a,
2002b; Yun et al., 2003). This vector, pSP6WNV-Not, was
assembled using overlap extension PCR, and restriction
endonuclease digestion using unique AvrII and XbaI sites in
the SP6WN/Xba parental vector. To minimize the potential
for recombination during cloning, plasmid propagation was
performed using Stbl2 rec bacteria (Invitrogen, Carlsbad,
CA) grown for 22–24 h at 30 8C in LB broth. To assess the
feasibility of introducing a reporter gene into this location of
the WNV genome, we inserted a PCR fragment containing
the EMCV IRES upstream of a fusion protein composed of
GFP and hygromycin B phosphotransferase (Hph), creating
the vector pWNV-IHF. The infectivity of both pSP6WNV-
Not and pSP6WNV-IHF RNAs was confirmed by monitor-
ing virus production and spread following the transfection
of BHK-21 cells with RNA synthesized in vitro (mMessage
mMachine SP6 kit, Ambion, Woodward, TX) (data not
shown). While these preliminary studies validated the
location selected for insertion of the IRES-reporter gene
cassette, in our hands, they were not an efficient means of
producing infectious virus particles.
Construction of a sub-genomic replicon cloning
intermediate
To transform the pSP6WNV-IHF molecular clone into a
sub-genomic replicon, we deleted the majority of the viral
structural proteins and replaced them with an autoprotease
of foot and mouth disease virus (Varnavski et al., 2000).
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unique ClaI and NsiI sites in pWNV-IHF (to create vector
pWrep2a-IHF).
Addition of a eukaryotic promoter
Two modifications of pWrep2a-IHF were required to
allow the expression of WNV RNAs capable of replication
in cells transfected with a WNV plasmid. To ensure the
WNV transcripts produced in cells terminated precisely at
the 3V end of the WNV cDNA, the hepatitis delta virus
ribozyme (Fodor et al., 1999) and a SV40 polyadenylation
signal were cloned adjacent to the 3Vterminus of the WNV
cDNA. A fragment containing these two components was
assembled using overlap extension PCR and cloned into a
unique XbaI site (blunted with mung bean nuclease) of
pWrep2a-IHF to create pWrep2aH-IHF. Next, the CMV
promoter/enhancer was inserted upstream of the first
nucleotide of the WNV genome using an overlap extension
PCR strategy and unique ClaI and NsiI sites in pWrep2aH-
IHF (creating pCWrep2aH-IHF).
Construction of an infectious WNV cDNA-expressing GFP
The final step in construction of a WNV reporter virus
involved re-inserting the sequence encoding the structural
genes of WNV into the sub-genomic replicon. This was
accomplished by inserting a PCR fragment amplified from
SP6WN/Xba into pCWrep2aH-IHF using unique BglII and
NsiI sites, generating an infectious molecular clone called
pWNII-IHF. A second-generation reporter virus, pWNII-
GFP was constructed by replacing the reporter gene cassette
of pWNII-IHF with an IRES2-EGFP fragment cloned
directly from pIRES2-GFP (BD Biosciences, Palo Alto,
CA). As a control, pWNII-Not was constructed by excision
of the reporter gene cassette from pWNII-IHF, followed by
intramolecular ligation. Electronic sequence information for
pWNII-GFP, pWNII-Not, and relevant cloning intermedi-
ates are available upon request.
Cell culture
Human embryonic kidney cells (HEK)-293T and HeLa
cells were maintained in Dulbecco’s Modified Essential
Media (DMEM) (Life Technologies, Gaithersburg, MD)
containing 10% fetal calf serum, and 1% penicillin/
streptomycin (P/S) (Invitrogen, Carlsbad, CA). Baby
hamster kidney cells (BHK-21) were cultured in Glasgow’s
Modified Essential Media, 10% trypsose phosphate broth,
5% FCS, 1% P/S (Doms laboratory), or DMEM 10% FCS,
1% P/S (Diamond laboratory).
Virus production
Infectious WNV was produced by transfection of HEK-
293T cells with DNA plasmids using Lipofectamine 2000
(Invitrogen, Carlsbad, CA) or LT1 (Mirus, Madison, WI).
Four hours after transfection, culture media was removedand replaced with a low glucose formulation of DMEM
(Life Technologies) containing 10% FCS and antibiotics.
Unless otherwise indicated, virus particles were harvested
at 48 h post-infection and clarified by filtration through
0.45 AM syringe filters. For long-term storage of virus
particles, virus-containing supernatants were mixed with an
equal volume of FCS containing 50 mM HEPES pH 8 and
stored at 80 8C. Virus titers were determined by plaque
assay on BHK-21 cells as described previously (Diamond
et al., 2003a).
Isolation and infection of human monocyte derived dendritic
cells
To generate immature human dendritic cells (iDCs),
elutriated monocytes (typically ~90% CD14-positive) were
obtained from the University of Pennsylvania Center for
AIDS Research, and cultured for 7–8 days in RPMI 1640
(Invitrogen, Carlsbad, CA) supplemented with 10% FCS,
100 U/ml penicillin/streptomycin and 2 mM l-glutamine
(Invitrogen, Carlsbad, CA), plus 10 ng/ml human GM-CSF
(Peprotech, Rocky Hill, NJ) and 20 ng/ml IL-4 (Peprotech,
Rocky Hill, NJ). Fresh medium was added to the iDCs on
days 3 and 6 as well as at the start of each experiment.
Dendritic cell purity was assessed by flow cytometry on day
6 and was typically 80–90% CD11chi, DC-SIGNhi, CD83-,
CD14-. For generation of mature, lipopolysaccharide (LPS)-
stimulated dendritic cells (mDCs), 100 ng/ml LPS was
added to the dendritic cells 48 h prior to infection and then
removed by several washes with media. Mouse IgG1-PE
isotype control antibody, anti-CD11c-PE, anti-CD14-PE,
and anti-CD83-PE were purchased from Caltag laboratories
(Burlingame, CA). Anti-IgG2a was obtained from BD
Biosciences Pharmingen (San Diego, CA). Anti-DC-
SIGN-PE was made by direct PE-conjugation of antibody
DC11 (Baribaud et al., 2001).
Culture and infection of rat superior cervical ganglion
sympathetic motor neurons
Primary sympathetic neuronal cultures were established
from superior cervical ganglia (SCG) of post-natal day 1 rats
using a previously described method (Easton et al., 1997).
Briefly, the dissected SCG were treated with 1 mg/ml
collagenase for 30 min at 37 8C followed by 2.5 mg/ml
trypsin for 30 min at 37 8C. The ganglia were then triturated
with a flame-polished Pasteur pipette. About 4000 cells were
plated in the center of a 35-mm dish that was pre-adsorbed
with rat collagen. The SCG cells were maintained in AM 50
media: Eagle’s minimal essential medium with Earle’s salts
(Life Technologies, Gaithersburg, MD), with the addition of
50 ng/ml mouse nerve growth factor (NGF) (Harlan
Bioproducts, Indianapolis, IN), 10% fetal bovine serum
(Sigma), 100 Ag/ml penicillin, 100 Ag/ml streptomycin, 20
AM fluorodeoxyuridine, and 20 AM uridine. SCG cells were
maintained for 7 days in culture prior to infection with WNV.
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rinsed extensively with PBS, and then cultured in AM 50
media. The relatively large inoculum of WNV was required
because of the very low confluence of SCG cells in culture
increases binding of virus to the bottom of the culture vessel,
rather than the plated cells. At 6 days post-infection, cells
were fixed and visualized directly with a Zeiss Axiovert 200
microscope for GFP fluorescence or permeabilized and
stained with a rat anti-WNV polyclonal antibody, and a Cy3-
conjugated goat anti-rat IgG secondary antibody (Jackson
Laboratories, Bar Harbor, ME).
Immunofluorescence analysis
HeLa cells were plated on glass coverslips and infected
with WNII-GFP for 30 h at a multiplicity of one. Cells were
washed once in room temperature PBS and fixed in 2%
paraformaldehyde (diluted in PBS) for 20 min, followed by
three washes with PBS. Next, cells were incubated with 50
mM NH4Cl for 10 min and washed in PBS. Permeabiliza-
tion of the cells was accomplished using 0.1% Triton X-100
in PBS (5 min), followed by three washes. To reduce non-
specific reactivity, cells were incubated in blocking solution
(5% FCS in PBS) for 30 min. Cells were stained using a
1/500 dilution of ascites fluid containing monoclonal
antibody 4G2 (Falconar, 1999) for 30 min, washed, and
then stained with Alexafluor 594 conjugated goat anti-
mouse secondary (30 min) (Molecular Probes, Eugene, OR).
After washing, the cells were imaged using a Nikon Elipse
E600 microscope at 60 magnification.
Intracellular FACS analysis
WNV envelope protein expression was measured in
infected cells using flow cytometry as described (Diamond
et al., 2000a, 2000b). Briefly, cells were infected with WNV
for the indicated times, harvested and washed with cold PBS.
Cells were fixed with and equal volume of 4% paraformal-
dehyde in PBS (10 min, room temperature), washed, and
permeabilized with 0.1% saponin in Hank’s balanced salt
solution (HBSS). To detect WNVantigen, cells were stained
with the WNV E1.E6 anti-E protein mAb (C. Doane and
M.S. Diamond, unpublished results) at a final concentration
of 10 Ag/ml for 1 h at 4 8C. Subsequently, cells were
washed thrice in HBSS containing saponin and incubated
a 1/500 dilution of Alexa 647-conjugated goat anti-
mouse IgG antibody (Molecular Probes, Eugene, OR) for
20 min at 4 8C. After additional washing, cells were
analyzed for E protein expression with a FacsCalibur
flow cytometer (BD Biosciences, Palo Alto, CA).
Analysis of WNV RNA
BHK-21 cells were plated in 12 well plates and infected
with WNV at a multiplicity of infection of 0.1. One hour
post-infection, cells were washed four times with 2 ml ofPBS. At the indicated times, total cellular RNAwas isolated
from infected cells using the RNAeasy kit (Qiagen, Valencia,
CA). The RNAwas treated with DNaseI for 30 min at room
temperature while bound to the column prior to elution in
RNAse-free water. RNA was then loaded into a single tube
RT-PCR reaction using primers that flank the site of the
reporter gene cassette (sense: 5VATTGTAGTGGAGGACA-
CTGTTTTG3V) and (antisense: 5VCTGACTTCCATTCTC-
AATAAATCC3V) (shown schematically in Fig. 6A). These
reactions were assembled using a commercial blend of
reverse transcriptase and Taq polymerase (Superscript III
One-step RT-PCR system, Invitrogen, Carlsbad, CA).
Reactions were incubated for 1 h at 50 8C to promote
cDNA synthesis. Next, a hot start was performed (94 8C,
3 min), followed by PCR amplification for 20 cycles with
the following conditions: 94 8C for 30 s, 50 8C for 30 s,
and 68 8C for 2 min. PCR products were analyzed using
agarose gel electrophoresis. To characterize PCR products
migrating faster than those of the anticipated size, bands
were cut from the gel and DNA isolated using a
QIAquick gel extraction kit (Qiagen, Valencia, CA).
PCR products were cloned into the PCR Blunt II
topoisomerase mediated cloning vector (Invitrogen, Carls-
bad, CA) and sequenced using M13 and T7 primers.Acknowledgments
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